Galmed Pharmaceuticals Ltd (GLMD.OQ)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|56||2011||Chairman of the Board|
|49||Chief Executive Officer, Director|
|39||Vice President – Drug Development|
|57||2012||Vice President - Regulatory|
|2015||Vice President - Clinical Operations|
- BRIEF-Galmed Pharmaceuticals Announces Pricing Of $6 Mln Registered Direct Offering
- BRIEF-Galmed Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
- BRIEF-Galmed Pharmaceuticals Q4 Loss Per Share $0.27
- BRIEF-Galmed Announces Arrive Study Data
- BRIEF-Galmed Pharmaceuticals To Provide Corporate Update At The Leerink Partners 7Th Annual Global Healthcare Conference